Literature DB >> 19404939

Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.

Peter J Wermuth1, Francesco Del Galdo, Sergio A Jiménez.   

Abstract

OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a severe fibrosing disorder occurring in patients with renal insufficiency. The majority of patients with this disorder have documented exposure to magnetic resonance imaging contrast agents containing Gd. The purpose of this study was to examine the effects of gadolinium diethylenetriaminepentaacetic acid bismethylamide (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3 on the expression and production of cytokines and growth factors by normal human peripheral blood monocytes in vitro and to examine whether conditioned media from Gd-exposed peripheral blood monocytes could induce a profibrotic phenotype in dermal fibroblasts.
METHODS: Normal human peripheral blood monocytes isolated by Ficoll-Hypaque gradient centrifugation and plastic adherence were incubated with various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3. Gene expression of interleukins 4, 6, and 13, interferon-gamma, tumor necrosis factor alpha, transforming growth factor beta, connective tissue growth factor, and vascular endothelial growth factor were assessed by real-time polymerase chain reaction (PCR) analysis. Production and secretion of cytokines and growth factors by Gd compound-exposed monocytes was quantified by enzyme-linked immunosorbent assay proteome multiplex arrays. The effects of conditioned media from the Gd compound-exposed monocytes on the phenotype of normal human dermal fibroblasts were examined by real-time PCR and Western blotting.
RESULTS: The 3 Gd-containing compounds stimulated the expression and production of numerous cytokines and growth factors by normal human peripheral blood monocytes. Conditioned media from these cells induced a profibrotic phenotype in normal human dermal fibroblasts.
CONCLUSION: The 3 Gd-containing compounds studied induce potent cellular responses in normal human peripheral blood monocytes, which may participate in the development of tissue fibrosis in NSF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404939      PMCID: PMC2737360          DOI: 10.1002/art.24471

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

1.  Array-based ELISAs for high-throughput analysis of human cytokines.

Authors:  M D Moody; S W Van Arsdell; K P Murphy; S F Orencole; C Burns
Journal:  Biotechniques       Date:  2001-07       Impact factor: 1.993

2.  Nephrogenic fibrosing dermopathy.

Authors:  S E Cowper; L D Su; J Bhawan; H S Robin; P E LeBoit
Journal:  Am J Dermatopathol       Date:  2001-10       Impact factor: 1.533

3.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

4.  Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy).

Authors:  Joshua M Levine; Robert A Taylor; Lauren B Elman; Shawn J Bird; Ehud Lavi; Ethan D Stolzenberg; Michael L McGarvey; Arthur K Asbury; Sergio A Jimenez
Journal:  Muscle Nerve       Date:  2004-11       Impact factor: 3.217

5.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

6.  Nephrogenic fibrosing dermopathy with systemic involvement.

Authors:  William W Ting; Mary Seabury Stone; Kathi C Madison; Kevin Kurtz
Journal:  Arch Dermatol       Date:  2003-07

7.  Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.

Authors:  Anand Khurana; John F Greene; Whitney A High
Journal:  J Am Acad Dermatol       Date:  2008-06-05       Impact factor: 11.527

8.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure.

Authors:  Richard D Swartz; Leslie J Crofford; Sem H Phan; Robert W Ike; Lyndon D Su
Journal:  Am J Med       Date:  2003-05       Impact factor: 4.965

9.  The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.

Authors:  T Steger-Hartmann; M Raschke; B Riefke; H Pietsch; M A Sieber; J Walter
Journal:  Exp Toxicol Pathol       Date:  2009-01-07

10.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

View more
  29 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

3.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

4.  The functional expression of calcium-sensing receptor in the differentiated THP-1 cells.

Authors:  Yu-hui Xi; Hong-zhu Li; Wei-hua Zhang; Li-na Wang; Li Zhang; Yan Lin; Shu-zhi Bai; Hong-xia Li; Ling-yun Wu; Rui Wang; Chang-qing Xu
Journal:  Mol Cell Biochem       Date:  2010-05-15       Impact factor: 3.396

5.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

6.  Porous Polymersomes with Encapsulated Gd-labeled Dendrimers as Highly Efficient MRI Contrast Agents.

Authors:  Zhiliang Cheng; Daniel L J Thorek; Andrew Tsourkas
Journal:  Adv Funct Mater       Date:  2009-12-09       Impact factor: 18.808

7.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

8.  Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

Authors:  Peter J Wermuth; Kellan R Carney; Fabian A Mendoza; Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Lab Invest       Date:  2017-03-27       Impact factor: 5.662

9.  Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury.

Authors:  William Jenkins; Patricia Perone; Kyle Walker; Narasimharao Bhagavathula; Muhammad Nadeem Aslam; Marissa DaSilva; Michael K Dame; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-04-12       Impact factor: 3.738

10.  Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells.

Authors:  Jin-Xia Li; Jing-Cheng Liu; Kui Wang; Xiao-Gai Yang
Journal:  J Biol Inorg Chem       Date:  2010-01-14       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.